Products for Research Use Only

Fosamprenavir

CAT: 0804-HY-78726-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-78726-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fosamprenavir is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir. Fosamprenavir is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir can be used for the study of human immunodeficiency virus (HIV-1) infection[1][2].
CAS Number
226700-79-4
Product Name Alternative
Amprenavir phosphate; GW 433908
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Drug Intermediate; HIV; HIV Protease
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Others
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/Fosamprenavir.html
Purity
99.94
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](OP(O)(O)=O)CN(S(=O)(C3=CC=C(N)C=C3)=O)CC(C)C
Molecular Formula
C25H36N3O9PS
Molecular Weight
585.61
Precautions
H315, H319, H320
References & Citations
[2]Johnston N, et al. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model. Laryngoscope. 2023 Jan;133 Suppl 1 (Suppl 1) :S1-S11.|[1]Hester EK, et al. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006 Jul-Aug;40 (7-8) :1301-10.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1
Citation 01
Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Research Square Print. 2022 May.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.